Sutab Disease Interactions
There are 15 disease interactions with Sutab (magnesium sulfate / potassium chloride / sodium sulfate).
- Depression
- Inflammatory bowel disease
- Intestinal obstruction disorders
- Cardiac disease
- Pregnancy
- Renal dysfunction
- Myasthenia gravis
- Dehydration/diarrhea
- Dehydration
- Familial periodic paralysis
- Hyperkalemia
- Renal dysfunction
- GI irritation
- Arrhythmias
- Acidosis
Anticonvulsants (applies to Sutab) depression
Major Potential Hazard, Moderate plausibility.
Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication. Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior. Caregivers and family should be alert for the emergence or worsening of symptoms. Behaviors of concern should be reported immediately to the healthcare providers.
References
- "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals (2002):
- "Product Information. Depakene (valproic acid)." Abbott Pharmaceutical (2001):
- "Product Information. Depakote (divalproex sodium)." Abbott Pharmaceutical (2001):
- "Product Information. Lamictal (lamotrigine)." Glaxo Wellcome (2001):
- "Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical (2001):
- "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals (2001):
- "Product Information. Vimpat (lacosamide)." UCB Pharma Inc (2008):
- "Product Information. Banzel (rufinamide)." Eisai Inc (2008):
- "Product Information. Aptiom (eslicarbazepine)." Sunovion Pharmaceuticals Inc (2013):
Laxatives (applies to Sutab) inflammatory bowel disease
Major Potential Hazard, Moderate plausibility.
The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.
References
- "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc (2001):
- "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet
- "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb
- "Product Information. Neoloid (castor oil)." Paddock Laboratories Inc (2001):
- "Product Information. SenoSol-X (senna)." Apothecon Inc (2022):
- "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories (2010):
Laxatives (applies to Sutab) intestinal obstruction disorders
Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction, Gastrointestinal Obstruction
The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.
References
- "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc (2001):
- "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet
- "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb
- "Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet (2001):
- "Product Information. Citrucel (methylcellulose)." SmithKline Beecham (2001):
- "Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc (2001):
- "Product Information. SenoSol-X (senna)." Apothecon Inc (2022):
- "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories (2010):
Magnesium IV (applies to Sutab) cardiac disease
Major Potential Hazard, High plausibility. Applicable conditions: Myocardial Infarction, Heart Block
The parenteral administration of magnesium is contraindicated in patients with heart block or heart damage from myocardial infarction. These conditions may be exacerbated during magnesium infusion. High serum levels of magnesium (> 4.5 mEq/L) can cause sinus bradycardia, AV block, nodal rhythms, and bundle branch block, which can progress to asystole and cardiac arrest at magnesium levels of approximately 14 mEq/L to 15 mEq/L. If parenteral magnesium is used in patients with preexisting conduction disturbances, it should be infused at a slower rate, and cardiac function and serum magnesium level should be closely monitored. The usual precautionary measures should be observed to prevent hypermagnesemia, and IV calcium salts (e.g., calcium gluconate), pressors, cardiac pacemakers, and equipment for supportive care should be immediately available in case of acute magnesium intoxication.
References
- Sherer DM, Cialone PR, Abramowicz JS, Woods JR Jr "Transient symptomatic subendocardial ischemia during intravenous magnesium sulfate tocolytic therapy." Am J Obstet Gynecol 166 (1992): 33-5
- Viskin S, Belhassen B, Laniado S "Deterioration of ventricular tachycardia to ventricular fibrillation after rapid intravenous administration of magnesium sulfate." Chest 101 (1992): 1445-7
- "Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical (2001):
Magnesium IV (applies to Sutab) pregnancy
Major Potential Hazard, Moderate plausibility. Applicable conditions: Pre-eclampsia/Eclampsia
Intravenous magnesium should not be given to mothers with preeclampsia during the two hours preceding delivery.
References
- "Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical (2001):
Magnesium salts (applies to Sutab) renal dysfunction
Major Potential Hazard, High plausibility.
Magnesium is eliminated by the kidney. The serum concentration of magnesium is increased in patients with renal impairment. Magnesium toxicity includes CNS depression, muscular paralysis, respiratory depression, hypotension and prolonged cardiac conduction time. Disappearance of the patellar reflex is a useful clinical sign of magnesium intoxication. Therapy with magnesium should be administered cautiously and dosages should be modified in patients with compromised renal function. Clinical monitoring of serum magnesium levels is recommended.
References
- "Product Information. Mag-Ox 400 (magnesium oxide)." Blaine Company Inc. (2001):
- "Product Information. Uro-Mag (magnesium oxide)." Blaine Company Inc. (2001):
- "Product Information. Slow-Mag (magnesium chloride)." Searle (2001):
- "Product Information. Magonate (magnesium gluconate)." Fleming and Company (2001):
- "Product Information. Losospan (magaldrate)." Whitehall-Robbins (2001):
Magnesium sulfate (applies to Sutab) myasthenia gravis
Major Potential Hazard, Moderate plausibility.
The use of magnesium sulfate is contraindicated in patients with myasthenia gravis as it can precipitate a myasthenic crisis. Myasthenic crisis is a life-threatening condition characterized by neuromuscular respiratory failure. Symptoms of myasthenic crisis may include difficulty swallowing, ptosis, facial droop, weakness and/or difficulty breathing that may require intubation.
References
- "Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical (2001):
Potassium chloride (applies to Sutab) dehydration/diarrhea
Major Potential Hazard, High plausibility.
Potassium chloride liquid suspension contains the stool softener, docusate sodium, as a dispersing agent. Clinical studies with potassium chloride liquid suspension indicate that minor changes in stool consistency may be common though usually well tolerated. However, patients may rarely experience diarrhea or cramping abdominal pain. Patients with severe or chronic diarrhea or who are dehydrated ordinarily should not be prescribed potassium chloride liquid suspension.
References
- "Product Information. K-Dur (potassium chloride)." Schering Corporation (2001):
Potassium salts (applies to Sutab) dehydration
Major Potential Hazard, High plausibility. Applicable conditions: Diarrhea
Administration of potassium salts in severe dehydration may predispose to renal impairment. Therapy with potassium salts should be administered cautiously in patients with acute dehydration (e.g., due to severe or prolonged diarrhea or heat stress). Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L). Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.
References
- "Product Information. K-Dur (potassium chloride)." Schering Corporation (2001):
- "Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical (2002):
- "Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb (2002):
- "Product Information. Kaon (potassium gluconate)." Savage Laboratories (2002):
Potassium salts (applies to Sutab) familial periodic paralysis
Major Potential Hazard, High plausibility.
Administration of potassium salts may precipitate attacks in familial hyperkalemic periodic paralysis or paramyotonia congenita. Therapy with potassium preparations should be administered cautiously in patients with these conditions.
References
- Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison's Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division (1998):
Potassium salts (applies to Sutab) hyperkalemia
Major Potential Hazard, High plausibility. Applicable conditions: Acidosis, Adrenal Insufficiency, Burns - External, Diabetes Mellitus, Hemolytic Anemia
The use of potassium salts is contraindicated in patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can lead to cardiac arrhythmias or arrest. Potassium therapy should be administered cautiously in patients with conditions predisposing to hyperkalemia, such as chronic renal failure, systemic acidosis, acute dehydration, hypoaldosteronism (e.g., due to primary adrenal insufficiency or congenital adrenal enzyme deficiency), uncontrolled diabetes mellitus, and extensive tissue breakdown (e.g., due to severe burns, intravascular hemolysis, tumor lysis syndrome, or rhabdomyolysis). Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L). Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.
References
- Kopman EA, Ramirez-Inawat RC "Persistent electromechanical cardiac arrest following administration of cardioplegic and glucose-insulin-potassium solutions." Anesth Analg 59 (1980): 69-71
- Chakko SC, Frutchey J, Gheorghiade M "Life-threatening hyperkalemia in severe heart failure." Am Heart J 117 (1989): 1083-91
- Lankton JW, Siler JN, Neigh JL "Letter: Hyperkalemia after administration of potassium from nonrigid parenteral-fluid containers." Anesthesiology 39 (1973): 660-1
- Illingworth RN, Proudfoot AT "Rapid poisoning with slow-release potassium." Br Med J 281 (1980): 485-6
- Wetli CV, Davis JH "Fatal hyperkalemia from accidental overdose of potassium chloride." JAMA 240 (1978): 1339
- Kallen RJ, Rieger CH, Cohen HS, Sutter MA, Ong RT "Near-fatal hyperkalemia due to ingestion of salt substitute by an infant." JAMA 235 (1976): 2125-6
- Saxena K "Death from potassium chloride overdose." Postgrad Med 84 (1988): 97-8,101-2
- Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40
- Lawson DH "Clinical use of potassium supplements." Am J Hosp Pharm 32 (1975): 708-11
- Perez GO, Oster JR, Pelleya R, Caralis PV, Kem DC "Hyperkalemia from single small oral doses of potassium chloride." Nephron 36 (1984): 270-1
- Cox J, Starbuck M "Hyperkalemic cardiac arrest during an infusion of potassium chloride following an overdose of propranolol." Resuscitation 14 (1986): 255-6
- Ceuppens H, Hitchcock JF, Damen J, Jambroes G, Ae Dion R "Severe hypotension due to potassium-induced pericardial injury." Thorax 37 (1982): 546-7
- "Product Information. K-Dur (potassium chloride)." Schering Corporation (2001):
- Schrier RW, Regal EM "Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease." Kidney Int 1 (1972): 156-68
- "Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company
- "Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals (2001):
- Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison's Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division (1998):
- "Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical (2002):
- "Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb (2002):
- "Product Information. Kaon (potassium gluconate)." Savage Laboratories (2002):
Potassium salts (applies to Sutab) renal dysfunction
Major Potential Hazard, High plausibility.
The use of potassium salts is contraindicated in patients with severe renal impairment characterized by oliguria, anuria, or azotemia. Since potassium is excreted by the kidney, the administration of potassium salts in such patients, particularly by the intravenous route, may produce hyperkalemia and cardiac arrhythmias or arrest. Therapy with potassium salts should be administered cautiously in patients with diminished renal function or other conditions which impairs potassium excretion (e.g. adrenal insufficiency). Close monitoring of serum potassium concentrations is recommended, as potentially fatal hyperkalemia can develop rapidly and is often asymptomatic, manifested only by an increased potassium level (6.5 to 8 mEq/L) and characteristic electrocardiographic changes (peaking of T waves, loss of P waves, depression of ST segment, prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L). Continuous or serial electrocardiography may be appropriate in some patients during replacement therapy, particularly if given intravenously.
References
- "Product Information. K-Dur (potassium chloride)." Schering Corporation (2001):
- "Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company
- "Product Information. Potassium Acetate (potassium acetate)." Abbott Pharmaceutical (2002):
- "Product Information. K-Lyte (potassium bicarbonate-potassium citrate)." Bristol-Myers Squibb (2002):
- "Product Information. Kaon (potassium gluconate)." Savage Laboratories (2002):
Potassium salts (oral) (applies to Sutab) GI irritation
Major Potential Hazard, High plausibility. Applicable conditions: Gastrointestinal Obstruction, Peptic Ulcer, Gastrointestinal Hemorrhage, History - Peptic Ulcer, Duodenitis/Gastritis, Gastrointestinal Perforation, Esophageal Disease
The use of all solid oral formulations of potassium is contraindicated in patients with arrested or delayed gastrointestinal (GI) transit, whether due to structural, pathological, or pharmacological causes. Potassium is irritating to the GI mucosa and may cause ulcerative and/or stenotic lesions during prolonged physical contact. Based on spontaneous adverse reaction reports, the frequency of small bowel lesions associated with enteric-coated preparations of potassium chloride is 40 to 50 per 100,000 patient-years, while that for wax matrix controlled-release formulations is less than one per 100,000 patient years. Esophageal ulceration has also been reported following administration of controlled-release formulations of potassium chloride in cardiac patients with esophageal compression due to enlarged left atrium. Potassium supplementation should be administered as a liquid preparation or as an aqueous suspension in patients with esophageal obstruction and/or delayed gastrointestinal transit time.
Because of ulcerogenic effects, oral potassium should be administered cautiously in patients with peptic ulcers or other upper gastrointestinal diseases associated with inflammation, bleeding, or perforation. Patients should be advised not to crush, chew, or break potassium tablets or capsules, and to take them with meals and a full glass of water or other liquid. Potassium liquids should be diluted prior to consumption.
References
- Mason SJ, O'Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981): 115-20
- Bronson DL, Gamelli RL "Jejunal ulceration and stricture due to wax-matrix potassium chloride tablets and amitriptyline." J Clin Pharmacol 27 (1987): 788-9
- Teplick JG, Teplick SK, Ominsky SH, Haskin ME "Esophagitis caused by oral medication." Radiology 134 (1980): 23-5
- Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967): 136-8
- Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966): 97-101
- Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967): 7-11
- Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966): 291-6
- Berg EH, Schuster F, Segal GA "Thiazides with potassium producing intestinal stenosis." Arch Surg 91 (1965): 998-1001
- Naiken VS, Rachman R "Giant ulcers of the transverse colon." JAMA 217 (1971): 344
- Ball JR "Letter: Potassium strictures of the upper alimentary tract." Lancet 1 (1976): 495-6
- Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965): 383-5
- Watts CD, Curry C, Randolph RP "Intestinal complications found from potassium chloride. Case report." J Natl Med Assoc 57 (1965): 492-3
- Jacobs E, Pringot J "Gastric ulcers due to the intake of potassium chloride." Am J Dig Dis 18 (1973): 289-94
- Eng J, Sabanathan S "Drug-induced esophagitis." Am J Gastroenterol 86 (1991): 1127-33
- Lambert JR, Newman A "Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy." Am J Gastroenterol 73 (1980): 508-11
- Lewis JH "Gastrointestinal injury due to medicinal agents." Am J Gastroenterol 81 (1986): 819-34
- Barloon TJ, Moore SA, Mitros FA "A case of stenotic obstruction of the jejunum secondary to slow- release potassium." Am J Gastroenterol 81 (1986): 192-4
- Watson MR, Mark JB "Ulceration of the small intestine. Relation to enteric-coated potassium." Am J Surg 112 (1966): 421-5
- Billig DM, Jordan GL Jr "Nonspecific ulcers of the small intestine." Am J Surg 110 (1965): 745-9
- Barkin JS, Harary AM, Shamblen CE, Lasseter KC "Potassium chloride and gastrointestinal injury." Ann Intern Med 98 (1983): 261-2
- Antonescu CG, Barritt AS 3d "Potassium chloride and gastric outlet obstruction." Ann Intern Med 111 (1989): 855-6
- Strom BL, Carson JL, Schinnar R, Sim E, Maislin G, Soper K, Morse ML "Upper gastrointestinal tract bleeding from oral potassium chloride. Comparative risk from microencapsulated vs wax-matrix formulations." Arch Intern Med 147 (1987): 954-7
- Peters JL "Benign oesophageal stricture following oral potassium chloride therapy." Br J Surg 63 (1976): 698-9
- Davies DR, Brightmore T "Idiopathic and drug-induced ulceration of the small intestine." Br J Surg 57 (1970): 134-9
- Ward C, Hamid S, Dow J "Gastric complication of massive Slow-K overdose." Br J Surg 74 (1987): 490
- Collins FJ, Matthews HR, Baker SE, Strakova JM "Drug-induced oesophageal injury." Br Med J 1 (1979): 1673-6
- Tresadern J, Rickwood AM, Spitz L "Multiple small bowel strictures in a child and accidental potassium chloride ingestion." Br Med J 2 (1977): 1124-5
- Moorhouse RA "Letter: Ulceration of small intestine and slow-release potassium tablets." Br Med J 3 (1975): 542
- Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206
- Ashby WB, Humphreys J, Smith SJ "Small-bowel ulceration induced by potassium chloride." Br Med J 5475 (1965): 1409-12
- Wynn V "Potassium chloride and bowel ulceration." Br Med J 5477 (1965): 1546
- Rosenthal T, Adar R, Militianu J, Deutsch V "Esophageal ulceration and oral potassium chloride ingestion." Chest 65 (1974): 463-5
- McMahon FG, Ryan JR, Akdamar K, Ertan A "Effect of potassium chloride supplements on upper gastrointestinal mucosa." Clin Pharmacol Ther 35 (1984): 852-5
- Brower RA "Jejunal perforation possibly induced by slow-release potassium in a patient with Crohn's disease." Dig Dis Sci 31 (1986): 1387-90
- Shuster F, Berg EH "Enteric-coated potassium and bowel obstruction." JAMA 194 (1965): 570
- McMahon FG, Ryan JR, Akdamar K, Ertan A "Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial." Lancet 2 (1982): 1059-61
- Learmonth I, Weaver PC "Letter: Potassium stricture of the upper alimentary tract." Lancet 1 (1976): 251-2
- Moorhouse RA "Letter: Potassium-induced stricture of the small bowel." Lancet 1 (1976): 365
- Roberts HJ "Potassium chloride and intestinal ulceration." Lancet 2 (1965): 1127
- Lakhani M, Stewart WK "Hazards of potassium chloride solution." Lancet 2 (1985): 453
- Leijonmarck CE, Raf L "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 56-7
- Hasker W, McCaffrey J "Ulceration of a Meckel's diverticulum due to a potassium chloride tablet." Med J Aust 2 (1972): 261-2
- Lubbe WF, Cadogan ES, Kannemeyer AH "Oesophageal ulceration due to slow-release potassium in the presence of left atrial enlargement." N Z Med J 90 (1979): 377-9
- Lawson DH "Adverse reactions to potassium chloride." Q J Med 43 (1974): 433-40
- Lofgren RP, Rothe PR, Carlson GJ "Jejunal perforation associated with slow-release potassium chloride therapy." South Med J 75 (1982): 1154-5
- Delaney T, Hoxworth PI "Enteric-coated potassium chloride enteropathy." Surg Gynecol Obstet 127 (1968): 76-80
- Hartman SW, Greaney EM Jr, Rottapel D "Small-bowel ulceration due to enteric-coated potassium ingestion in a two-year-old child." Surgery 61 (1967): 814-5
- Riker J, Swanson M, Schweigert B "Esophageal ulceration caused by wax-matrix potassium chloride." West J Med 128 (1978): 542-3
- Leijonmarck CE, Fenyo G, Raf L "Nontraumatic perforation of the small intestine." Acta Chir Scand 150 (1984): 405-11
- Leijonmarck CE, Raf L "Ulceration of the small intestine due to slow-release potassium chloride tablets." Acta Chir Scand 151 (1985): 273-8
- Raf LE "Enteric-coated potassium chloride tablets and ulcer of the small intestine." Acta Chir Scand Suppl 374 (1967): 32-50,73-74,76-77
- Phillips BL "Potassium-induced bowel ulceration." Br J Clin Pract 28 (1974): 143-4
- Trewby PN "Drug-induced peptic ulcer and upper gastrointestinal bleeding." Br J Hosp Med 23 (1980): 185-8,190
- Sinar DR, Bozymski EM, Blackshear JL "Effects of oral potassium supplements on upper gastrointestinal mucosa: multicenter clinical comparison of three formulations and placebo." Clin Ther 8 (1986): 157-63
- Moore JG, Alsop WR, Freston JW, Tolman KG "The effect of oral potassium chloride on upper gastrointestinal mucosa in healthy subjects: healing of lesions despite continuing treatment." Gastrointest Endosc 32 (1986): 210-2
- Lech Y, Hey H, Jorgensen F, Matzen P, Ostergaard O "Evaluation of the ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss." J Clin Pharmacol 27 (1987): 206-9
- Folk FS, Spellman MW, Hoffler OW "Stenosing small bowl ulceration. Apparently secondary to enteric- coated potassium chloride." J Natl Med Assoc 61 (1969): p315-8assim
- Sandor F "Complications of "slow-K" therapy." J R Coll Gen Pract 26 (1976): 595-8
- Emerson DN "Potassium therapy and gastrointestinal lesions." Nebr State Med J 55 (1970): 518-23
- Henry JG, Shinner JJ, Martino JH, Cimino LE "Fatal esophageal and bronchial artery ulceration caused by solid potassium chloride." Pediatr Cardiol 4 (1983): 251-2
- Skoutakis VA, Acchiardo SR, Wojciechowski NJ, Carter CA "Liquid and solid potassium chloride: bioavailability and safety." Pharmacotherapy 4 (1984): 392-7
- Javett S "Slow k ulcer." S Afr J Surg 13 (1975): 64
- Strahan J, Sweeney PJ "A case of small bowel perforation." Ulster Med J 34 (1965): 22
- Graham DY, Smith JL, Bouvet AA "What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations." J Pharm Sci 79 (1990): 420-4
- Trechot P, Moore N, Bresler L, Castot A, Gay G, Netter P, Royer R "Potassium chloride tablets and small bowel stenoses and perforations: two studies in the french pharmacovigilance system." Am J Gastroenterol 89 (1994): 1268
- "Potassium chloride and bowel ulceration." Br Med J 5475 (1965): 1383-4
- McLoughlin JC "Gastrointestinal lesions and potassium chloride supplements." Lancet 1 (1985): 581-2
- "Small-intestine ulceration and enteric-coated potassium chloride." Med Lett Drugs Ther 7 (1965): 57-8
- Weiss SM, Rutenberg HL, Paskin DL, Zaren HA "Gut lesions due to slow-release KCI tablets." N Engl J Med 296 (1977): 111-2
- "Potassium and gastrointestinal lesions. I." Nutr Rev 24 (1966): 138-41
- "Product Information. K-Dur (potassium chloride)." Schering Corporation (2001):
- "Product Information. Urocit-K (potassium citrate)." Mission Pharmacal Company
- "Product Information. Kaon (potassium gluconate)." Savage Laboratories (2002):
Osmotic laxatives preparations (applies to Sutab) arrhythmias
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Electrolyte Abnormalities, Seizures, Electrolyte Abnormalities, Seizures
The use of osmotic laxatives preparations, containing sodium sulfate, potassium sulfate, and magnesium sulfate may cause cardiac arrhythmias. There have been rare reports of serious arrhythmias associated with the use of ionic osmotic laxative products for bowel preparation. Patients with electrolyte abnormalities should have them corrected before treatment is initiated. Use caution when prescribing preparations in patients at increased risk of arrhythmias or with a history of seizures. It is recommended to conduct a pre-dose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.
References
- "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories (2010):
Potassium chloride (applies to Sutab) acidosis
Moderate Potential Hazard, High plausibility.
Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt (i.e. acetate, bicarbonate, citrate, or gluconate) rather than potassium chloride, since alkali therapy helps to promote cellular uptake of potassium. Close monitoring of acid-base balance, serum electrolytes, electrocardiogram, and clinical status is recommended.
References
- Leiter LA, Josse RG, West ML, Halperin ML "Severe metabolic acidosis induced in a patient during fasting by KCl administration." Clin Invest Med 11 (1988): 266-70
- "Product Information. K-Dur (potassium chloride)." Schering Corporation (2001):
- Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison's Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division (1998):
Sutab drug interactions
There are 530 drug interactions with Sutab (magnesium sulfate / potassium chloride / sodium sulfate).
Sutab alcohol/food interactions
There is 1 alcohol/food interaction with Sutab (magnesium sulfate / potassium chloride / sodium sulfate).
More about Sutab (magnesium sulfate / potassium chloride / sodium sulfate)
- Sutab consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (70)
- Drug images
- Side effects
- Dosage information
- FDA approval history
- Drug class: laxatives
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.